Foghorn Therapeutics Inc. (FHTX) 8-K Current Report: February 23, 2026
Filed: February 23, 2026
Health Care
Pharmaceutical PreparationsFoghorn Therapeutics Inc. (FHTX) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 8.01: Other Events
Foghorn Therapeutics Inc. 8-K Feb 23, 2026 Event Analysis
Item 5.02 · Departure/Election of Directors or Officers
- • Ryan D. Maynard appointed CFO effective Feb 23, 2026; replaces interim CFO Jeff Sacher
- • Base salary $510,000 with 40% target annual bonus (~$204,000) and $90,000 signing bonus
- • Stock option grant for 400,000 shares at market-price strike; 25% vests at 1-year, remaining 75% quarterly over 3 years
- • Maynard brings deep biotech CFO experience: Cara Therapeutics, Rigel Pharmaceuticals (16 years), and LetsGetChecked
- • Permanent CFO hire signals operational stability — interim leadership transition complete
Item 8.01 · Other Events
- • Press release filed Feb 23, 2026 announcing management changes — details in Exhibit 99.1
- • Leadership transitions at clinical-stage biotechs can signal strategic pivots or pipeline reprioritization
Other Foghorn Therapeutics Inc. 8-K Filings
Get deeper insights on Foghorn Therapeutics Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.